Archive for January, 2008

Are you aware of SAMPL?

Saturday, January 26th, 2008

Greetings,

My name is Aniko Simon, and I am one of the co-founders of SimBioSys. Those of you who know SimBioSys will know that one of our primary areas of focus is virtual screening and we have been developing the eHiTS software for a number of years. Some scientists have referred to us as the “unknown contender” and, unfortunately, it is true to say that relative to some of the other players in the marketplace (for example, CCG, Schrodinger, OpenEye) we are not as well known. We are working on this and this blog is one of our efforts to further our exposure and communication to the market. We hope that the quality and performance of our software speaks for itself however but that needs to be based on a users’ experience and with so many applications to choose from who has the chance to test and compare everything?

We receive a lot of feedback from our users. A fraction of this is made public via publications or talks (http://www.simbiosys.ca/ehits/ehits_enrichment.html and http://www.simbiosys.ca/ehits/ehits_validation.html)

We encourage healthy competition. We have good relationships with the majority of vendors in the marketplace and have much mutual respect for their intellectual prowess and scientific intentions. We enjoy the prospect of comparing the performance of our own solutions with theirs. It is excellent when we have the chance to participate in comparisons. Unfortunately it is all too common to not be contacted by scientists conducting such comparisons and we only get to compare our capabilities with those of other tools after publications are issued.

An example of this situation is described on our website at present (http://www.simbiosys.ca/ehits/ehits_enrichment.html). eHiTS was recently evaluated on 11 targets of pharmaceutical interest in collaboration with Merck Research Laboratories. The original study (without eHiTS) was published last year http://dx.doi.org/10.1021/ci700052x. A later evaluation by Merck of eHiTS on the same set revealed that eHiTS overall performed very well across those 11 families. In particular, it outperformed all the other programs tested on the Carbonic Anhydrase I family. The eHiTS performance average for the entire test set was 18.7, which was the highest average amongst all the tested programs, that included Glide, Fred and Flog.

Just yesterday we discovered another party was going on… ….this one conducted by a vendor. OpenEye are the developers of the excellent Fred docking program (http://www.eyesopen.com/products/applications/fred.html). They are also in the midst of the SAMPL-1 project…the Statistical Assessment of the Modeling of Proteins and Ligands. Details are available online here (http://sampl.eyesopen.com/) but an extract is here:

“SAMPL is a blind test of protein and ligand modeling; an analysis of methods on data not seen by participants. “With SAMPL we intend to avoid ‘who won, who lost’,” explained Dr. Anthony Nicholls, President and CEO of OpenEye Scientific Software. “Rather, we see this as an opportunity for groups to test their methods, learn from the experience and share lessons learned.” In addition, third party testers, particularly professional modelers, are encouraged to participate so as to allow comparisons of single methods when used by several, independent, participants.

SAMPL-1 will consist of two sets of protein-ligand binding data, generously provided by Abbott Labs and Vertex Pharmaceuticals, and sixty-three vacuum-water transfer energies, courtesy of Peter Guthrie at the University of Western Ontario, and Chemical Computing Group. The two sets of protein-ligand data each have between twenty and seventy active compounds, the majority with protein-ligand crystal structures. The assessment will consist of three parts:

1. Virtual Screening.
2. Predicting binding poses.
3. Predicting binding affinities.”

VERY EXCITING!

For those of you interested in this area you can see that such an effort would be of interest to us..and indeed it is! However, we just found out about it yesterday (Jan 25th, 2008) and, based on what we see, everything needs to be submitted by Feb 19th 2008, about 3 work weeks. Quote “The results of SAMPL-1 will be presented at the CUP IX meeting, March 17th-19th in Santa Fe. All participants will be offered a speaking slot at the meeting. The deadline for submission of results is on February 18th, 2008, one month before the CUP IX meeting. For more details, please see http://sampl.eyesopen.com/.”

We’re confused since the announcement went out on Nov 1st to SOME people (we NOW found some blog posts on the web about it). But only became aware of it via these newswire posts yesterday Jan 25th 2008: (http://www.centredaily.com/business/technology/story/355727.html, http://www.newsobserver.com/1566/story/901427.html). Grrrr. Now we have to figure out if and how to participate. This is very short notice for us especially since we have other meetings and tasks lined up already. We’re going to contact OpenEye and ask whether there is a way to get an extension…other informed participants knew the project was coming for 3 months…we just found out and are just not ready. However, we do want to attend the party. It sounds like an excellent opportunity for rigorous examination. We’ll keep you informed about our decision and path forward but either way we encourage you to watch SAMPL-1. The results should be very interesting. Even if we can’t participate we will do a follow up study later when the data are made available.

Watch this space.

“Roping in” you next scaffold hop with LASSO

Tuesday, January 22nd, 2008

Just a quick note to let you know about the web-release of a JCAMD paper on LASSO. LASSO is a 2.5D ligand-based similarity search tool that uses surface properties of known active molecules to build a model for screening large databases for molecules with similar properties. The tool is extremely fast, screening a database of a million molecules in under 1 minute on a standard 1CPU machine (such as my laptop). The main advantage of LASSO is the fact that it is independent of the underlying 2D skeleton or the 3D conformation. Thus it has the ability to retrieve molecules with very different 2D scaffolds (chemotypes) and you do not need a bioactive conformation.

Read more about LASSO in the paper “LASSO—ligand activity by surface similarity order: a new tool for ligand based virtual screening”
http://dx.doi.org/10.1007/s10822-007-9164-5

LASSO is based on the surface points illustrated as triangles in this image

Also visit the LASSO website for more information, or to try LASSO for yourself:
LASSO Website

Welcome … Hello world … Lets begin the discussion!

Wednesday, January 9th, 2008

Happy New Year, welcome to 2008 and welcome to the SimBioSys Blog! I hope this blog will serve two main goals:

  1. Act as a place where users and friends of SimBioSys can come to find out what we at SimBioSys are up to
  2. [And I believe most importantly] I hope this blog is the start of more communication with those in the computational drug discovery / design field.

I will be posting my thoughts and ideas, things I find interesting and I hope you will make comments and we can have an open discussion.

I guess it would be a good idea to introduce myself, my name is Darryl Reid and I am an Application Scientist here at SimBioSys. I will very likely be doing most of the posting to this blog, however I have extended the offer for others within SimBioSys to put in their two cents as they see fit.

I also see this blog as one of my first steps into the chemistry / chemistry software blogging community. Therefore if you have a blog which you feel might be of interest to myself or other visitors to the SimBioSys Blog, please feel free to add a link in the comments section.

Obviously this blog is hosted on the SimBioSys website and will be influenced/biased by the experience and opinions of SimBioSys personnel.

However, it will be my intent to discuss things openly on this blog and, while comments will be monitored, allow for differing opinions. I just ask that people maintain a level of professionalism (please call me on it if you see me faltering on that myself).

In the coming weeks and months I will be posting some interesting notes on some special projects we are working on at SimBioSys and some potentially controversial opinions on molecular docking and the direction we (as a community) should be going. I hope you will stay tuned.

Once again, Happy New Year to everyone, I wish you all success in 2008.

Darryl :)